CellSearch 与 ISET 检测转移性癌患者循环肿瘤细胞的直接比较。
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.
机构信息
Translational Research Laboratory, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France.
出版信息
Br J Cancer. 2011 Sep 6;105(6):847-53. doi: 10.1038/bjc.2011.294. Epub 2011 Aug 9.
BACKGROUND
Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we compared the performance of two CTC detection systems based on the expression of the EpCAM antigen (CellSearch assay) or on cell size (ISET assay).
METHODS
Circulating tumour cells were enumerated in 60 patients with metastatic carcinomas of breast, prostate and lung origins using CellSearch according to the manufacturer's protocol and ISET by studying cytomorphology and immunolabelling with anti-cytokeratin or lineage-specific antibodies.
RESULTS
Concordant results were obtained in 55% (11 out of 20) of the patients with breast cancer, in 60% (12 out of 20) of the patients with prostate cancer and in only 20% (4 out of 20) of lung cancer patients.
CONCLUSION
Our results highlight important discrepancies between the numbers of CTC enumerated by both techniques. These differences depend mostly on the tumour type. These results suggest that technologies limiting CTC capture to EpCAM-positive cells, may present important limitations, especially in patients with metastatic lung carcinoma.
背景
循环肿瘤细胞（CTCs）可提供有关患者预后和治疗效果的信息。但是，目前尚无通用的检测 CTC 的方法。在这里，我们比较了两种基于 EpCAM 抗原表达（CellSearch 检测）或细胞大小（ISET 检测）的 CTC 检测系统的性能。
方法
使用 CellSearch 按照制造商的方案，通过研究细胞形态学和用抗细胞角蛋白或谱系特异性抗体进行免疫标记，对 60 例转移性乳腺癌、前列腺癌和肺癌患者的循环肿瘤细胞进行了计数。使用 ISET。
结果
在 20 例乳腺癌患者中，有 55%（11 例）的患者结果一致，在 20 例前列腺癌患者中，有 60%（12 例）的患者结果一致，而在 20 例肺癌患者中，只有 20%（4 例）的患者结果一致。
结论
我们的结果突出了两种技术计数的 CTC 数量之间存在重要差异。这些差异主要取决于肿瘤类型。这些结果表明，将 CTC 捕获限制在 EpCAM 阳性细胞的技术可能存在重要的局限性，尤其是在转移性肺癌患者中。
Zotero 插件